Arca Biopharma slows losses, R&D expenses in Q2
BOULDER — Arca Biopharma Inc. (Nasdaq: ABIO) saw its losses for the second quarter of 2022 shrink by 33%, to $3.2 million from a $4.8 million net loss in the second quarter of 2021. That’s according to the quarterly report released by the drug manufacturer Wednesday.
Arca also more than halved its research and development expenses year-over-year, to $1.4 million from $3.5 million.
This comes as the company is exploring a merger or sale of assets; it established a committee to weigh these options amid a 2021 that saw it double its year-over-year losses.
Arca has two drugs in its pipeline: COVID-19 drug…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
